An Innovative Immune Score-Based Prognostic Nomogram for Patients with Cervical Cancer

Table 2

Univariate analyses of OS among cervical cancer patients based on clinicopathological features and immune scores.

		OS
Characteristics	Total	Survival	Death	HR (95% CI)	value
Age (y)^a
≤40	66	56 (84.8)	10 (15.1)	1.000
40-50	61	46 (75.4)	15 (24.5)	1.511 (0.679, 3.365)	0.312
50-60	39	33 (84.6)	6 (15.3)	0.921 (0.334, 2.538)	0.874
60-70	22	16 (72.7)	6 (27.2)	1.551 (0.562, 4.278)	0.396
70-80	9	5 (55.5)	4 (44.4)	3.680 (1.145, 11.828)	0.029
>80	1	1 (100.0)	0 (0.0)	-	0.998
Immune scores
≤374.3	97	73 (75.2)	24 (24.7)	1.000
374.3 to 1051.6	60	48 (80.0)	12 (20.0)	0.813 (0.405, 1.632)	0.560
>1051.6	41	36 (87.8)	5 (12.1)	0.360 (0.137, 0.946)	0.038
Race
Asian	20	18 (90.0)	2 (10.0)	1.000
White	146	116 (79.4)	30 (20.5)	1.295 (0.308, 5.448)	0.725
Others	32	23 (71,8)	9 (28.1)	1.605 (0.343, 7.502)	0.548
Grade
I	15	13 (86.6)	2 (13.3)	1.000
II	96	71 (73.9)	25 (26.0)	1.611 (0.380, 6.826)	0.517
III	86	72 (83.7)	14 (16.2)	1.199 (0.271, 5.302)	0.811
IV	1	1 (100.0)	0 (0.0)	-	0.997
Stage
I	123	99 (80.4)	24 (19.5)	1.000
II	41	34 (82.9)	7 (17.0)	1.149 (0.491, 2.691)	0.748
III	22	19 (86.3)	3 (13.6)	1.204 (0.360, 4.023)	0.763
IV	12	5 (41.6)	7 (58.3)	6.944 (2.924, 16.488)	1.12-05
Histology
Cervical squamous cell carcinoma	158	124 (78.4)	34 (21.5)	1.000
Cervical nonsquamous cell carcinoma	40	33 (82.5)	7 (17.5)	1.103 (0.401, 2.050)	0.813

Abbreviations: CI: confidence interval; ^aAge at diagnosis of cervical cancer.